Biopure is the organization connected with the innovative work of substitute blood in the restorative market. Oxyglobin and Hemopure are the two results of the organization under discourse. Oxyglobin is a substitute item for creatures, and Hemoglobin is made for the human market. The rationale of Biopure is to enter the human market with a developmental substitute for blood, helping in the transfusion procedure around the world. Oxyglobin has been affirmed by the FDA; though, the organization needs to sit tight for the endorsement of Hemopure by FDA, an essential prerequisite before the dispatch of each medicinal item. Oxyglobin and Hemopure have the same physical qualities and appear to be like each other. The dispatch of Oxyglobin at a low cost would bring about a lower value desire for Hemopure, bringing about the loss of the potential benefit of the organization. The planning and evaluating of Oxyglobin ought to be composed in a manner that the capability of Hemopure is not risked in the market.